Vandetanib clinical trials
Also written Zactima, ZD6474, Caprelsa and SAR390530.
How each study uses vandetanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 6 Apr 2011 · CAPRELSA · NDA 022405 (FDA, Drugs@FDA)
- European Union
- 16 Feb 2012 · Caprelsa · EMEA/H/C/002315 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
98 studies that test it; most in 2008 (20)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 16 |
| 2007 | 19 |
| 2008 | 20 |
| 2009 | 8 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 9 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 43 · Other 55
Genzyme, a Sanofi Company (35) · Sanofi (8) · National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (6) · Dana-Farber Cancer Institute (4) · Samsung Medical Center (2) · SWOG Cancer Research Network (2) · St. Jude Children's Research Hospital (2)
Often tested with
Tested in the same studies.
Carboplatin (4) · Everolimus (3) · Gemcitabine (3) · Oxaliplatin (3) · Imatinib (3) · Fluorouracil (2) · Paclitaxel (2) · Docetaxel (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Vandetanib is the comparator. A study of two new drugs counts under both.
- 1Selpercatinib · Loxo Oncology, Inc.
Studies
Open first, then newest update. How each study uses vandetanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 98
- Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT01582191Written as VandetanibHow we know
- To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompletedPhase 4SanofiNCT01496313Written as 300mg vandetanibHow we know
- An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedPhase 3Genzyme, a Sanofi CompanyNCT00410761Written as ZD6474 (Vandetanib)How we know
- Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic CarcinomaCompletedPhase 2University of LiverpoolNCT01601808Written as Caprelsa (vandetanib)How we know
- Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedPhase 3Genzyme, a Sanofi CompanyNCT00418886Written as VandetanibHow we know
- Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid CancerCompletedPhase 3Genzyme, a Sanofi CompanyNCT01876784Written as Vandetanib (SAR390530)How we know
- Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerCompletedPhase 2Genzyme, a Sanofi CompanyNCT00537095Written as VandetanibHow we know
- Effect of Vandetanib on Cellular Markers in Invasive Breast CancerTerminatedPhase 2Ronald WeigelNCT01934335Written as VandetanibHow we know
- A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)CompletedPhase 1Cancer Research UKNCT01586624Written as Vandetanib, SelumetinibHow we know
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT03630120Written as VandetanibHow we know
- Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT02495103Written as VandetanibHow we know
- A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by SurgeryCompletedPhase 1Fox Chase Cancer CenterNCT01183559Written as VandetanibHow we know
- Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck LesionsCompletedPhase 2University of ChicagoNCT01414426Written as vandetanibHow we know
- Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00514046Written as VandetanibHow we know
- Vandetanib in Advanced NSCLC With RET RearrangementCompletedPhase 2Samsung Medical CenterNCT01823068Written as VandetanibHow we know
- HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)Status unknownNot applicableAmsterdam UMC, location VUmcNCT02239952Written as vandetanibHow we know
- Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal TumorsCompletedPhase 2National Cancer Institute (NCI)NCT02015065Written as VandetanibHow we know
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownPhase 2Samsung Medical CenterNCT02638428Written as VandetanibHow we know
- Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung CancerCompletedPhase 2Hoosier Cancer Research NetworkNCT00613626Written as ZD6474How we know
- ZD6474 to Treat Advanced Brain Cancer in PatientsCompletedPhase 1National Cancer Institute (NCI)NCT00272350Written as ZD6474How we know
See all 98 studies that test vandetanib →
Given beside what is tested · 5 — vandetanib is usual care or a partner of the new treatment
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as VandetanibHow we know
- Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentCompletedPhase 3SanofiNCT01298323Written as VandetanibHow we know
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as VandetanibHow we know
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167Written as VandetanibHow we know
- A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)TerminatedPhase 1/2National Cancer Institute (NCI)NCT00923247Written as VandetanibHow we know
As the comparator · 2 — what is tested is compared with vandetanib
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingPhase 3Loxo Oncology, Inc.NCT04211337Written as VandetanibHow we know
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288Written as VandetanibHow we know
Codes
What other systems call vandetanib · ClinicalTrials.gg INT004437
- MeSH (NLM) C452423vandetanibConfirmed NLM, Wikidata
- UNII (FDA) YO460OQ37KVANDETANIBConfirmed FDA, NLM, Wikidata
- RxNorm 1098413Confirmed FDA, Wikidata
- Wikidata Q7914515vandetanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2737VandetanibOne source FDA
- DrugBank DB05294One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C452423 | vandetanib | Confirmed NLM, Wikidata |
| UNII (FDA) | YO460OQ37K | VANDETANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1098413 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7914515 | vandetanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2737 | Vandetanib | One source FDA |
| DrugBank | DB05294 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.